vVARDIS Announces $35 Million Financing with Global Healthcare Investor OrbiMed to Roll Out Curodont, an Innovative Drill-Free Treatment for Early Tooth Decay

ZUG, SWITZERLAND – EQS Newswire – 11 February 2025 – vVARDIS, a Swiss high growth dental company, and OrbiMed, a leading healthcare investment firm, today announced the closing of a $35 million financing. The capital will support the company’s growth initiatives and global commercial expansion. vVARDIS is a developer and manufacturer of unique dental products under the Curodont brand, including their innovative drill-free treatment for early tooth decay. Today tooth decay remains number one disease in the world according to the World Health Organization. Last year’s rapid expansion of sales, with an initial focus on the U.S., already has thousands of dental clinics using the product and over 300,000 teeth treated in 2024. vVARDIS’ technology is already incorporated in lectures of renowned universities in the U.S. and Europe as a new standard of care for the treatment of early tooth decay.

The partnership between OrbiMed and vVARDIS is based on the shared vision to build a U.S. and global leader in innovative dental products. With the market shifting from invasive to non-invasive care combined with the accelerated adoption of AI-detection of early tooth decay, vVARDIS products are well-timed to market trends. These innovative products allow dental practices to treat early tooth decay in 5 to 10 minutes, saving dental professionals and patients hours of chair time.

“We are confident that vVARDIS has the scientific knowledge and capabilities to become a global powerhouse in the dental market. With its proprietary formulas and its Curodont™ products, the company is positioned to grow fast in this market and to provide a drill-free option for early tooth decay. The growth ambition of the company and its focus on providing innovative solutions in a global dental market are at the core of our investment strategy,” said Matthew Rizzo, General Partner, OrbiMed.

“We are thrilled about the partnership with OrbiMed. The funding and the expertise they bring will enhance our abilities to better serve dental professionals and patients and to fulfill our vision to create a world where treatment of early decay is pain-free, regenerative and accessible to everyone. As dentists, we are excited to finally offer a solution for the treatment of early decay. Dental professionals have been waiting for decades for a drill-free treatment of early decay. Curodont™ has the potential to broaden the scope of options offered by dental practices and empowering them to enhance patient care.” commented Drs. Haley and Goly Abivardi, Founders and co-CEOs of vVARDIS.

William Blair & Company acted as the exclusive financial advisor to vVARDIS and McGuireWoods and Rüd Winkler acted as legal counsel.

The issuer is solely responsible for the content of this announcement.